Tuesday, May 28, 2013    |    BIO-IT World    |    Archives    |    Advertising   |    CHI Conferences    |    Subscribe 


Too Much to Ignore: Anne Wojicicki’s Plan for Health Care and Big Data

Bio-IT World | STANFORD, CA—The challenge in healthcare is to change what is—and what isn’t—a billable
question, said 23andMe founder Ann Wojicicki, giving the opening keynote yesterday at the Big Data in
Biomedicine conference at Stanford University. And they key will be generating so much data that we’re
forced to figure it out. Read More

CPT Code Concerns Raise Issues for Diagnostics Industry

Bio-IT World | With the plummeting cost of next-generation sequencing (NGS) expanding the range of clinical
 genomics tests being offered by diagnostics companies and medical centers, a looming problem lies in
reimbursement. Read More

Transforming Your Business Defined

Bio-IT World | Guest Commentary | Transform your business before it’s transformed for you. These words
convey a hard truth about modern business—external forces are rapidly conspiring to unravel even the best-laid
plans. From geopolitical and economic macro trends to global threats to health and the environment, business
change is now maddeningly unpredictable and capricious. Absent a proactive plan to address these new business
eealities, some businesses are in for challenging futures. Read More


US the Least Risky Spot for Your Data Center

Computerworld | An survey of 30 countries finds the US to be the least risky place to open a data center, followed
by the UK, Germany and Sweden. The most risky spots were Indonesia, India, and Brazil. Read More

PatientsLikeMe Launches Open Research Platform

InformationWeek | PatientsLikeMe has launched its Open Research Exchange and issued a call for patients, an
initiative funded by a Robert Wood Johnson Foundation grant announced earlier this year. Read More

The Gene Test Question

New York Times | Angelina Jolie announced drastic action this week--a preventive double mastectomy after
learning that she carries a faulty copy of BRCA1. But this type of action isn't available to all women, thanks to the
high costs of gene tests. Read More